Document is current

Any future updates will be listed below

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study

Crossref DOI link: https://doi.org/10.1186/s13223-023-00805-3

Published Online: 2023-06-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark